Orphan drugs in development for primary biliary cirrhosis: challenges and progress

References

• Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American association for the study of liver diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349–359.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188.
   PubMed Web of Science ®Google Scholar
• Addison T, Gull W. On a certain affection of the skin – vitiligoidea-alpha plana, beta tuberosa. Guys Hosp Rep. 1851;7:265–276.
   Google Scholar
• Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53–61.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525–3531.
   PubMed Web of Science ®Google Scholar
• Moteki S, Leung PS, Dickson ER, et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology. 1996;23:436–444.
   PubMed Web of Science ®Google Scholar
• Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev. 2014;13:441–444.
   PubMed Web of Science ®Google Scholar
• Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology. 1998;27:656–661.
   PubMed Web of Science ®Google Scholar
• Shibata M, Onozuka Y, Morizane T, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol. 2004;39:255–259.
   PubMed Web of Science ®Google Scholar
• Al-Jabri AA, Al Belushi MS, Nsanze H. Frequency and levels of autoantibodies in healthy adult Omanis. Ann Saudi Med. 2003;23:372–375.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, García-Carrasco M, Brito MP, López-Soto A, Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 2003;12:341–355.
   PubMed Web of Science ®Google Scholar
• Carey EJ. Cholestatic Liver Disease. New York: Springer; 2014.
   Google Scholar
• Björnsson E, Kalaitzakis E, Neuhauser M, et al. Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver Int. 2010;30:251–258.
   PubMed Web of Science ®Google Scholar
• Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490–494.
   PubMed Web of Science ®Google Scholar
• Newton JL. Fatigue in primary biliary cirrhosis. Clin Liver Dis. 2008;12:367–383;ix.
   Web of Science ®Google Scholar
• Stanca CM, Bach N, Krause C, et al. Evaluation of fatigue in US patients with primary biliary cirrhosis. Am J Gastroenterol. 2005;100:1104–1109.
   PubMed Web of Science ®Google Scholar
• Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol. 2006;44:776–783.
   PubMed Web of Science ®Google Scholar
• Bergasa NV. Pruritus of cholestasis. In: Carstens E, Akiyama T, editors. Itch: Mechanisms and Treatment. Boca Raton, FL: 2014. Chapter 6.
   Google Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology. 1990;11:884–887.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;1:297–302.
   PubMed Web of Science ®Google Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003–1006.
   PubMed Web of Science ®Google Scholar
• Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53:911–917.
   PubMed Web of Science ®Google Scholar
• Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006;55:536–541.
   PubMed Web of Science ®Google Scholar
• Jones EA. Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opin Pharmacother. 2008;9:645–651.
   PubMed Web of Science ®Google Scholar
• Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol. 1999;11:623–631.
   Web of Science ®Google Scholar
• Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006;44:91–98.
   PubMed Web of Science ®Google Scholar
• Newton JL, Pairman J, Sutcliffe K, Wilton K, Jones DE. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2008;6:228–233.
   Google Scholar
• Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35:636–641.
   PubMed Web of Science ®Google Scholar
• Zein CO, McCullough AJ. Association between fatigue and decreased survival in primary biliary cirrhosis. Gut. 2007;56:1165–1166.
   PubMed Web of Science ®Google Scholar
• Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574–576.
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161–167.
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol. 1999;41:431–434.
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679–684.
   PubMed Web of Science ®Google Scholar
• Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407.
   PubMed Web of Science ®Google Scholar
• Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323–332.
   PubMed Web of Science ®Google Scholar
• Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–493.
   PubMed Web of Science ®Google Scholar
• Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36:216–220.
   PubMed Web of Science ®Google Scholar
• Van Itallie TB, Hashim SA, Crampton RS, Tennent DM. The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine. N Engl J Med. 1961;265:469–474.
   PubMed Web of Science ®Google Scholar
• Pells G, Mells GF, Carbone M, et al; UK-PBC Consortium. The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. J Hepatol. 2013;59:67–73.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. International Autoimmune Hepatitis Group. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385.
   PubMed Web of Science ®Google Scholar
• Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301.
   PubMed Web of Science ®Google Scholar
• Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104:1420–1425.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007;102:1244–1250.
   PubMed Web of Science ®Google Scholar
• Siegel JL, Luthra H, Donlinger J, Angulo P, Lindor K. Association of primary biliary cirrhosis and rheumatoid arthritis. J Clin Rheumatol. 2003;9:340–343.
   PubMed Web of Science ®Google Scholar
• Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2014;48(2–3):192–197.
   Web of Science ®Google Scholar
• Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303–330.
   PubMed Web of Science ®Google Scholar
• Prince MI, Chetwynd A, Diggle P, Jarner M, Metcalf JV, James OF. The geographical distribution of primary biliary cirrhosis in a well-defined cohort. Hepatology. 2001;34:1083–1088.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chrétien Y, Chazouillères O, Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162–169.
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Selmi C, Worman HJ, et al; USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–1202.
   PubMed Web of Science ®Google Scholar
• Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology. 2001;33:16–21.
   PubMed Web of Science ®Google Scholar
• Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59:508–512.
   PubMed Web of Science ®Google Scholar
• Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites. Hepatology. 2006;43:525–531.
   PubMed Web of Science ®Google Scholar
• Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J. 1980;281:772–775.
   PubMed Web of Science ®Google Scholar
• Tsuji K, Watanabe Y, Van De Water J, et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun. 1999;13:171–178.
   PubMed Web of Science ®Google Scholar
• Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME. Innate immunity and primary biliary cirrhosis. Curr Mol Med. 2009;9:45–51.
   PubMed Web of Science ®Google Scholar
• Palmer JM, Kirby JA, Jones DE. The immunology of primary biliary cirrhosis: the end of the beginning? Clin Exp Immunol. 2002;129:191–197.
   Web of Science ®Google Scholar
• Lohr H, Fleischer B, Gerken G, Yeaman SJ, Meyer zum Büschenfelde KH, Manns M. Autoreactive liver-infiltrating T cells in primary biliary cirrhosis recognize inner mitochondrial epitopes and the pyruvate dehydrogenase complex. J Hepatol. 1993;18:322–327.
   PubMed Web of Science ®Google Scholar
• Shimoda S, Van de Water J, Ansari A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998;102:1831–1840.
   PubMed Web of Science ®Google Scholar
• Van de Water J, Ansari A, Prindiville T, et al. Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med. 1995;181:723–733.
   PubMed Web of Science ®Google Scholar
• Van de Water J, Ansari AA, Surh CD, et al. Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol. 1991;146:89–94.
   PubMed Web of Science ®Google Scholar
• Van de Water J, Turchany J, Leung PS, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest. 1993;91:2653–2664.
   PubMed Web of Science ®Google Scholar
• Chuang YH, Lian ZX, Tsuneyama K, et al. Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun. 2006;26:232–240.
   Web of Science ®Google Scholar
• Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA. Immunogenicity of biliary epithelium: study of the adhesive interaction with lymphocytes. Gastroenterology. 1997;112:968–977.
   PubMed Web of Science ®Google Scholar
• Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology. 1997;26:1399–1405.
   PubMed Web of Science ®Google Scholar
• Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S13–S20.
   PubMed Web of Science ®Google Scholar
• Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178:175–186.
   PubMed Web of Science ®Google Scholar
• Allen K, Kim ND, Moon JO, Copple BL. Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling. Toxicol Appl Pharmacol. 2010;243:63–67.
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001;35:134–146.
   PubMed Web of Science ®Google Scholar
• Fickert P, Fuchsbichler A, Marschall HU, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol. 2006;168:410–422.
   PubMed Web of Science ®Google Scholar
• Azer SA, Coverdale SA, Byth K, Farrell GC, Stacey NH. Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. J Gastroenterol Hepatol. 1996;11:208–215.
   Web of Science ®Google Scholar
• Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis. 2011;31:147–156.
   PubMed Web of Science ®Google Scholar
• Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46:785–792.
   PubMed Web of Science ®Google Scholar
• Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology. 2011;54:714–723.
   Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42:655–657.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544–2555.
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Selmi C, Poli F, et al; Italian PBC Genetic Study Group. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology. 2008;48:1906–1912.
   Web of Science ®Google Scholar
• Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42:658–660.
   PubMed Web of Science ®Google Scholar
• Mells GF, Floyd JA, Morley KI, et al. UK PBC Consortium, Wellcome Trust Case Control Consortium 3. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011;43:329–332.
   PubMed Web of Science ®Google Scholar
• Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980;78:236–246.
   PubMed Web of Science ®Google Scholar
• Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994;20:707–713.
   PubMed Web of Science ®Google Scholar
• Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2003;7:779–794.
   PubMedGoogle Scholar
• Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865–870.
   PubMed Web of Science ®Google Scholar
• Springer J, Cauch-Dudek K, O’Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47–53.
   PubMed Web of Science ®Google Scholar
• Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044–1051.
   PubMed Web of Science ®Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al; Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate endpoints of outcomes of patients with primary biliary cirrhosis – an international follow-up study. Gastroenterology. 2014;47(6):1338.e–1349.e.
   Google Scholar
• Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology. 1999;29:39–43.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877.
   PubMed Web of Science ®Google Scholar
• Rydning A, Schrumpf E, Abdelnoor M, Elgjo K, Jenssen E. Factors of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol. 1990;25:119–126.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135–1144.
   PubMed Web of Science ®Google Scholar
• Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979;20:137–140.
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Lammers WJ, van Buuren HR, et al; On behalf of the Global PBC Study Group. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2015;pii:gutjnl-2014-308351.
   Google Scholar
• Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989;96:1552–1559.
   PubMed Web of Science ®Google Scholar
• Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol. 2003;39:142–148.
   PubMed Web of Science ®Google Scholar
• Tinmouth J, Tomlinson G, Heathcote EJ, Lilly L. Benefit of transplantation in primary biliary cirrhosis between 1985–1997. Transplantation. 2002;73:224–227.
   Web of Science ®Google Scholar
• Imam MH, Silveira MG, Sinakos E, et al. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:182–185.
   Web of Science ®Google Scholar
• Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2008;20:5–9.
   Web of Science ®Google Scholar
• Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 1997;26:1138–1142.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology. 2008;48:1149–1156.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:259–264.
   Web of Science ®Google Scholar
• Tomiyama Y, Takenaka K, Kodama T, et al. Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis. Intern Med. 2013;52:1553–1559.
   Web of Science ®Google Scholar
• Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644–647.
   PubMed Web of Science ®Google Scholar
• Batts KP, Jorgensen RA, Dickson ER, Lindor KD. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Am J Gastroenterol. 1996;91:2314–2317.
   Web of Science ®Google Scholar
• Combes B, Carithers RL Jr, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766.
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149–1156.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med. 1991;324:1548–1554.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–890.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994;330:1342–1347.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–1140.
   PubMed Web of Science ®Google Scholar
• Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011;121:523–544.
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol Suppl. 1994;204:1–15.
   PubMedGoogle Scholar
• Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology. 1997;112:226–235.
   Web of Science ®Google Scholar
• Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001;121:170–183.
   PubMed Web of Science ®Google Scholar
• Zollner G, Wagner M, Moustafa T, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 2006;290:G923–G932.
   PubMed Web of Science ®Google Scholar
• Salvioli G, Lugli R, Pradelli JM, Frignani A, Boccalletti V. Urinary excretion of bile acids during acute administration in man. Eur J Clin Invest. 1988;18:22–28.
   PubMed Web of Science ®Google Scholar
• Takikawa H, Beppu T, Seyama Y. Urinary concentrations of bile acid glucuronides and sulfates in hepatobiliary diseases. Gastroenterol Jpn. 1984;19:104–109.
   Google Scholar
• Schuetz EG, Strom S, Yasuda K, et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001;276:39411–39418.
   PubMed Web of Science ®Google Scholar
• Matern S, Matern H, Farthmann EH, Gerok W. Hepatic and extrahepatic glucuronidation of bile acids in man. Characterization of bile acid uridine 5′-diphosphate-glucuronosyltransferase in hepatic, renal, and intestinal microsomes. J Clin Invest. 1984;74:402–410.
   PubMed Web of Science ®Google Scholar
• Huang J, Bathena SP, Tong J, Roth M, Hagenbuch B, Alnouti Y. Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010;40:184–194.
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Fuchsbichler A, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol. 2003;39:480–488.
   PubMed Web of Science ®Google Scholar
• Renner EL, Lake JR, Cragoe EJ Jr, Van Dyke RW, Scharschmidt BF. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors. Am J Physiol. 1988;254:G232–G241.
   Google Scholar
• Knyrim K, Vakil N, Pfab R, Classen M. The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man. Hepatology. 1989;10:134–142.
   PubMed Web of Science ®Google Scholar
• úriz M, Sáez E, Prieto J, Medina JF, Banales JM. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS One. 2011;6:e28717.
   PubMed Web of Science ®Google Scholar
• Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52:1489–1496.
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992;16:358–364.
   PubMed Web of Science ®Google Scholar
• Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology. 1993;18:165–172.
   PubMed Web of Science ®Google Scholar
• Neuman M, Angulo P, Malkiewicz I, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol. 2002;17:196–202.
   PubMed Web of Science ®Google Scholar
• Okada K, Shoda J, Taguchi K, et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295:G735–G747.
   PubMed Web of Science ®Google Scholar
• Ishizaki K, Iwaki T, Kinoshita S, et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol. 2008;578:57–64.
   PubMed Web of Science ®Google Scholar
• Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D. Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells. Int J Cancer. 2006;118:532–539.
   PubMed Web of Science ®Google Scholar
• Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990;11:12–15.
   PubMed Web of Science ®Google Scholar
• Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol. 1991;86:1194–1199.
   PubMed Web of Science ®Google Scholar
• Yokomori H, Oda M, Wakabayashi G, Kitajima M, Ishii H. Ursodeoxycholic acid therapy attenuated expression of adhesion molecule in primary biliary cirrhosis. Intern Med. 2003;42:1259–1261.
   Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720.
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD, Therneau TM, et al. Utilization of the mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115–121.
   PubMedGoogle Scholar
• Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32:790–795.
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, de Vries RA, et al; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–1287.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–1367.
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–2194.
   PubMed Web of Science ®Google Scholar
• Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895.
   PubMed Web of Science ®Google Scholar
• Fan M, Wang X, Xu G, Yan Q, Huang W. Bile acid signaling and liver regeneration. Biochim Biophys Acta. 2014;1849(2):196–200.
   Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.
   PubMed Web of Science ®Google Scholar
• Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233–236.
   PubMed Web of Science ®Google Scholar
• Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull. 2011;34:1885–1889.
   PubMed Web of Science ®Google Scholar
• Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594–2603.
   PubMed Web of Science ®Google Scholar
• Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591.
   PubMed Web of Science ®Google Scholar
• Kanda T, Foucand L, Nakamura Y, et al. Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells. Biochem J. 1998;330(pt 1):261–265.
   PubMed Web of Science ®Google Scholar
• Gong YZ, Everett ET, Schwartz DA, Norris JS, Wilson FA. Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proc Natl Acad Sci U S A. 1994;91:4741–4745.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(751–61):e8.
   Google Scholar
• Wiesner RH, Porayko MK, Dickson ER, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1992;16:1290–1299.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Assis DN, Boyer JL. On fibrates and cholestasis: a review. Hepatology. 2015;62(2):635–643.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2013;57:1691–1693.
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527–550.
   PubMed Web of Science ®Google Scholar
• Duval C, Fruchart JC, Staels B. PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss. 2004;97:665–672.
   Google Scholar
• Thomas M, Burk O, Klumpp B, et al. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARalpha). Mol Pharmacol. 2013;83:709–718.
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Tsuda K, Ueta H. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res. 1999;16:12–18.
   Web of Science ®Google Scholar
• Halliday JS, Chapman RW. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue! J Gastroenterol Hepatol. 2011;26:1345–1346.
   PubMed Web of Science ®Google Scholar
• Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21:1840–1845.
   PubMed Web of Science ®Google Scholar
• Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem. 2003;278:32852–32860.
   PubMed Web of Science ®Google Scholar
• Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol Pharmacol. 2005;67:1257–1267.
   PubMed Web of Science ®Google Scholar
• Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem. 2002;277:30559–30566.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL. Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59:1030–1042.
   PubMed Web of Science ®Google Scholar
• Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 2000;275:36703–36707.
   PubMed Web of Science ®Google Scholar
• Mennone A, Soroka CJ, Cai SY, et al. Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology. 2006;43:1013–1021.
   PubMed Web of Science ®Google Scholar
• Chai J, He Y, Cai SY, et al. Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology. 2012;55:1485–1494.
   PubMed Web of Science ®Google Scholar
• Singh VK, Mehrotra S, Narayan P, Pandey CM, Agarwal SS. Modulation of autoimmune diseases by nitric oxide. Immunol Res. 2000;22:1–19.
   PubMed Web of Science ®Google Scholar
• Sanz-Cameno P, Medina J, García-Buey L, et al. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol. 2002;37:723–729.
   PubMed Web of Science ®Google Scholar
• Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J Gastroenterol Hepatol. 2002;17:308–315.
   PubMed Web of Science ®Google Scholar
• Battista S, Bar F, Mengozzi G, et al. Evidence of an increased nitric oxide production in primary biliary cirrhosis. Am J Gastroenterol. 2001;96:869–875.
   Web of Science ®Google Scholar
• Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol. 2005;40:157–163.
   PubMed Web of Science ®Google Scholar
• Hirano Y, Hirano F, Fujii H, Makino I. Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation. Eur J Pharmacol. 2002;448:19–26.
   PubMed Web of Science ®Google Scholar
• Zhang B, Hu M, Zhang P, et al. BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis. Braz J Med Biol Res. 2013;46:433–439.
   PubMed Web of Science ®Google Scholar
• Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol. 2006;41:502–503.
   PubMed Web of Science ®Google Scholar
• Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931–1941.
   PubMed Web of Science ®Google Scholar
• Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44:371–373.
   PubMed Web of Science ®Google Scholar
• Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573–578.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol. 2002;97:212–214.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95:2990–2992.
   PubMed Web of Science ®Google Scholar
• Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34:197–203.
   PubMed Web of Science ®Google Scholar
• Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95:326–327.
   PubMed Web of Science ®Google Scholar
• Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver. 2001;21:223–224.
   PubMedGoogle Scholar
• Takeuchi Y, Ikeda F, Fujioka S, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011;26:1395–1401.
   PubMed Web of Science ®Google Scholar
• Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol. 2002;97:1075–1077.
   PubMed Web of Science ®Google Scholar
• Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004;10:894–898.
   PubMed Web of Science ®Google Scholar
• Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis. 2012;13:219–224.
   PubMed Web of Science ®Google Scholar
• Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33:235–242.
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J. 2010;4:120–126.
   PubMedGoogle Scholar
• Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97:2147–2149.
   PubMed Web of Science ®Google Scholar
• Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110:423–431.
   PubMed Web of Science ®Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010;120:69–75.
   PubMed Web of Science ®Google Scholar
• McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435–459.
   PubMed Web of Science ®Google Scholar
• Martini L. Encyclopedia of Endocrine Diseases. Amsterdam; Boston: Elsevier Academic Press; 2004.
   Google Scholar
• Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest. 2008;118:695–709.
   PubMed Web of Science ®Google Scholar
• Leuschner M, Güldütuna S, You T, Hübner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol. 1996;25:49–57.
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology. 1989;10:420–429.
   PubMed Web of Science ®Google Scholar
• Mollmann HW, Barth M. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer; 1996.
   Google Scholar
• Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918–925.
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Kärkkäinen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747–752.
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Färkkilä M, Neuvonen M, et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1545–1552.
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;31:318–323.
   PubMed Web of Science ®Google Scholar
• Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196–202.
   PubMed Web of Science ®Google Scholar
• Rabahi N, Chrétien Y, Gaouar F, et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol. 2010;34:283–287.
   PubMedGoogle Scholar
• Dall’Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus. 2004;13:372–376.
   PubMed Web of Science ®Google Scholar
• Anwer MS, Stieger B. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch. 2014;466:77–89.
   PubMed Web of Science ®Google Scholar
• Potter GD. Bile acid diarrhea. Dig Dis. 1998;16:118–124.
   Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714–719.
   PubMed Web of Science ®Google Scholar
• Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014;46:302–312.
   PubMedGoogle Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435–9440.
   PubMed Web of Science ®Google Scholar
• Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008;372:78–84.
   PubMed Web of Science ®Google Scholar
• Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45:695–704.
   PubMed Web of Science ®Google Scholar
• Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem. 2010;391:785–789.
   PubMed Web of Science ®Google Scholar
• Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 2005;39:S111–S124.
   PubMed Web of Science ®Google Scholar
• Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology. 2005;42:420–430.
   PubMed Web of Science ®Google Scholar
• Takeyama Y, Uehara Y, Inomata S, et al. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int. 2009;29:406–414.
   Web of Science ®Google Scholar
• Hofmann AF, Zakko SF, Lira M, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology. 2005;42:1391–1398.
   PubMed Web of Science ®Google Scholar
• Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130:465–481.
   PubMed Web of Science ®Google Scholar
• Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58:1201–1208.
   PubMed Web of Science ®Google Scholar
• Sombetzki M, Fuchs CD, Fickert P, et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol. 2015;62:871–878.
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799–1807.
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354:1053–1060.
   PubMed Web of Science ®Google Scholar
• Giljaca V, Stimac D, Gluud C. Are levels of alkaline phosphatases and bilirubin surrogate markers of outcomes of patients with primary biliary cirrhosis? Gastroenterology. 2015;148:860.
   PubMed Web of Science ®Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605–613.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549–1557.
   PubMed Web of Science ®Google Scholar
• Floreani A, Cazzagon N, Martines D, Cavalletto L, Baldo V, Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis. 2011;43:887–892.
   PubMedGoogle Scholar
• Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198–208.
   PubMed Web of Science ®Google Scholar
• Poupon R, Corpechot C. Elastography-based assessment of primary biliary cirrhosis staging. Dig Liver Dis. 2011;43:839–840.
   PubMedGoogle Scholar